In this study, we performed correlation analysis of polycomb gene EED and hematologic malignancies using the omics and clinical data of acute myeloid leukemia (LAML) and diffuse large B-Cell lymphoma (DLBC) from TCGA database. We found that: (1) High EED mRNA level was associated with poor prognosis and high CALGB cytogenetics risk of LAML patients. (2) EED mRNA level in DLBC cancer cells was higher than control cells. (3) EED gene expression could be regulated by both copy number alterations and DNA methylation. (4) Additionally, there were different EED co-expression genes nets in the two kinds of hematologic malignancies. In all, we confirmed that there are potential clinical significance of EED gene in pathogenesis and prognosis of hematologic malignancies.
Introduction
Polycomb repressive complex 1 and 2 (PRC1 and PRC2) are canonical chromatin silencing related protein complex created by different PcG gene assemblies, which can maintain the transcriptional repression of target genes through H3K27me3 and H2AK119Ub chromatin modification. Abnormal Expression and inactivation of Polycomb group (PcG) genes have been considered as important causes of hematological malignancies including acute myeloid leukemia (LAML) and diffuse larger B-cell lymphoma (DLBC) due to the derepression of pro-oncogenes (Iwama 2017) . Embryonic Ectoderm Development (EED) protein is the core component of Polycomb group protein family, which is the essential PCR2 structural protein and has direct interaction with PRC1 (Cao et al. 2014; Margueron & Reinberg 2011) . Besides, it cloud regulate gene expression by interaction with histone deacetylases (Ai et al. 2017) . So, we guess that EED gene could play vital roles in hematopoiesis and hematological malignancies.
LAML is characterized by ectopic proliferation of myeloblasts in the bone marrow with highly clinical heterogeneity. LAML is defined as 8 subtypes (M0-M7) according to the French-American-British (FAB) classification (Bennett et al. 1976) . LAML is frequently occurred in older adults, but only 10-20% LAML patients with more than 60-year old possess more than 5 year overall survival after receiving cytarabine-based chemotherapy or hematopoietic stem cell transplant treatment (Yang & Wang 2018) . DLBC is the most prevalent non-Hodgkin lymphoma (NHL) in adulthood with high malignancy and aggressiveness. DLBC is genetically heterogeneous, the somatic mutation identity among different DLBC patients is only 10-20%.
The roles of PcG genes in LAML are elusive. High expression of EZH2 gene, coding PRC2 catalytic subunit, is associated with extramedullary infiltration in LAML and EZH2 silencing suppresses cell proliferation, cell migration and increases cell apoptosis in LAML through inhibiting MMP2 expression and increasing E-cadherin expression (Zhu et al. 2016) . However, lower EZH2 expression also correlates with poorer prognosis of LAML patients due to loss of EZH2 inhibits the expression of HOX gene and results in enhancing chemo-resistance of LAML cell lines (Gollner et al. 2017) . Additionally, LAML patients with EZH2 mutations predict unfavorable prognosis with worse overall survival and relapse-free survival (Saygin et al. 2018 ).
In DLBC cancer cells, the high H3K27me3 level is significantly correlated with EZH2 protein level and predicts inferior overall survival (Oh et al. 2014) , and high level of H3K27me3 in bone marrow resident cells was also correlated with poor progression-free survival and overall survival of DLBC patients (Oh et al. 2016; Oh et al. 2014) . However, significant correlation between single PRC2 gene and DLBC prognosis have not been reported up to now.
To our knowledge, the corresponding published articles reporting correlation among EED gene expression and prognosis of hematologic malignancies is absent. In our previous study, we found that conditional knockout of Eed gene impairs fetal hematopoiesis including erythropoiesis and formation of hematopoietic progenitor and stem cells (Shi et al. 2013 ).
Based on our previous study and current articles, we propose the hypothesis that EED expression might correlate with the pathogenesis or prognosis of LAML and DLBC patients. In this study, omics data including transcriptome profiling, DNA methylation, single nucleotide polymorphism, copy number variant and clinical data of LAML and DLBC patients were retrieved from TCGA database, aiming to investigate prognostic significance of EED in LAML and DLBC patients, and preliminarily decipher the potential pathogenesis mechanism of EED involved in hematologic malignancies. 
Materials and Methods

Patients and omics data
Survival analysis
In LAML, 149 patients had both of survival information and EED expression data were incorporate into the survival analysis. In DLBC, 47 patients had both of OS information and EED expression data were incorporate into the OS survival analysis, and 45 DLBC patients had both of RFS information and EED expression data were incorporate into the RFS survival analysis. Some patients were excluded from survival analysis due to absent record of survival information or EED expression.
The correlation analysis between EED expression level and OS or RFS times of patients with LAML or DLBC was calculated with log-rank test of Kaplan-Meier survival analysis.
EED co-expressed genes screening
In our work, pearson and spearman scores among the expression of EED and other genes in respective LAML patients and DLBC patients was calculated, those genes with pearson and spearman scores > 0.4 or < -0.4 were identified as EED co-expressed genes. The KEGG signaling pathways of EED co-expressed genes were enriched, and the correlation network among EED co-expressed genes and signaling pathways were visualized by Cytoscape 3.6.1 software (http://www.cytoscape.org/). 
Statistical analysis
Results
EED mRNA level were upregulated in DLBC patients
According to the TCGA and GTEx data combined analysis, we found that EED mRNA level were significantly upregulated more than 10 fold in DLBC cancer cells compared with the paired normal cells (p < 0.01, Figure However, we did not find that the statistical association between EED mRNA level and the overall survival (OS), between EED level and recurrence-free survival (RFS) times of DLBC patients through Kaplan-Meier survival analysis ( Figure S1B , S1C). And, we did not find the statistical association between EED mRNA level and the clinicopathological characteristics (such as age, gender, bone marrow involvement, clinical stage, and recurrence status) of DLBC patients (Table S1 ). Besides, the EED mRNA level was not statistical difference between patients with clinical stage I and II and patients with clinical stage III and IV. In the univariate analysis, we also did not find the statistical association between EED mRNA level and the OS, between EED level and RFS times of DLBC patients (Table S2) .
EED mRNA level were associated with LAML risk and prognosis
In spite of EED mRNA level did not changed obviously in LAML cancer cells ( Figure 1A ), we found that EED mRNA level in LAML-M3 subtype ( Figure 2C , acute promyelocytic leukemia, APL)
were significantly lower than other LAML subtypes (M0-M4, p = 0.0005, Kruskal-Wallis test). APL patients were more susceptible to hemorrhage than other LAML subtypes, which could be caused by vascular invasion of APL cancer cells containing lower EED mRNA level. It seems that lower EED mRNA level could increase the metastasis and invasion potential of APL cancer cells. Viewed together with this hypothesis, we found that haploinsufficiency of EED gene in mouse caused by conditional deletion or mutant knockin could also increase the metastasis and invasion risk of leukemia cells (Ikeda et al. 2016; Ueda et al. 2016 ).
EED mRNA level were also associated with cancer and leukemia group B (CALGB) cytogenetics risk category of LAML, for EED mRNA level in the high risk (poor) group were significantly higher than the low risk (favorable) group ( Figure 2B , p = 0.0038, Mann Whitney test). And, in the Kaplan-Meier survival analysis, we found that LAML patients with high EED mRNA level had worse prognosis than LAML patients with low EED mRNA level ( Figure 2A , p = 0.0033, Log-rank test).
Besides, we found that there was significantly statistical association between EED mRNA level and some clinicopathological parameters (including CLAGB cytogenetics risk category and recurrence status) of LAML patients (p < 0.01, Table 1 ). And, in the univariate and multivariate analysis, we also found EED mRNA level, similar with age and CLAGB cytogenetics risk category, had significantly statistical association with the OS times of LAML patients (p < 0.01, Table 2 ). These results indicated that EED mRNA level, which similar with CALGB risk category, could be an independent LAML prognostic factor.
Genetic and epigenetic factors involved in the EED mRNA level changes
To analyze the causes of EED mRNA level changes, we searched the genetic variation of EED gene in our study population at first. Unfortunately, only one missense mutation (p.Leu196Gln) was found in the LAML group, which is located on the WD40 domain of EED protein and could impair the binding of EED protein and EZH2 protein. However, copy number alterations of EED gene had been found both in DLBC and LAML patients, and the subjects with increased copy number alterations of EED gene showed significantly higher EED mRNA level than the subjects with normal diploid of EED gene ( Figure 3A and 3B). However, there was no directly statistical association between EED copy number additions and survival times of LAML and DLBC patients ( Figure S2 ), EED mRNA level could be regulated both in genetics and epigenetics factors beyond itself alterations of EED gene.
In the epigenetics analysis, we found that the DNA methylation status of EED gene were obviously different between LAML and DLBC cancer cells ( Figure S3) , and DNA methylation level of EED gene was positive associated with EED mRNA level in DLBC instead of LAML cancer cells ( Figure   3C -D).
The EED related regulatory networks in DLBC and LAML patients
To study the differences of EED mediated gene regulatory networks in LAML and DLBC cancer cells, we Filtered out the EED co-expression genes in LAML and DLBC cancer cells respectively by person and spearman scores (both absolute values was not lower than 0.4). Accounting to the results, there were 1069 EED co-expression genes in LAML cancer cells, but only 54 genes were co-expressed with EED gene in DLBC cancer cells, and there were only 2 co-expression genes (XRCC5 and ZNF252P) were shared among LAML and DLBC groups ( Figure 4A ). Those results indicated that there could are different EED related gene regulatory networks in DLBC and LAML cancer cells. Besides, it was interesting that there were only 80 EED co-expression genes were negative correlation with EED genes in LAML cancer cells.
KEGG pathway analysis of the EED co-expressed genes showed that, EED gene could regulated the LAML pathological processes mainly through the cell proliferation and chromatin homeostasis related pathways, such as cell cycle, DNA replication, Fanconi anemia, homologous recombination, nucleotide excision repair, and mismatch repair ( Figure 4B and Table S3 ); but in DLBC cancer cells, EED could regulated the immunological response to the bacterial infections ( Figure 4C and Table   S4 ).
Discussion
In our work, we found there was none of statistically difference of EED expression among LAML patients and normal subjects, but EED was significantly increased in DLBC patients compared with normal subjects. In LAML, expression of EED in LAML M3 subtype (also named as acute promyelocytic leukemia, APL) was obviously decreased compared with other LAML subtypes. In the TCGA clinical dataset, LAML patients were grouped into poor prognosis group, favorable prognosis group and intermediate/normal prognosis group according to the CALGB cytogenetics risk category. EED expression was significantly up-regulated in CALGB poor prognosis group compared with CALGB favorable prognosis group. Moreover, higher expression level of EED gene predicts shorter overall survival in LAML patients.
Our findings echoed some published articles. High expression of EZH2 gene is involved in extramedullary infiltration in LAML and silencing of EZH2 suppresses cell proliferation/migration and increases cell apoptosis in LAML (Zhu et al. 2016) . Suppression of PRC2 subunits EED, SUZ12
or EZH1/EZH2 results in proliferation arrest and differentiation of leukemia cells (Shi et al. 2013 heterozygotes increases in the clonogenic capacity and bone marrow repopulating activity of hematopoietic stem/progenitor cells and is susceptible to leukemia through depressing Lgals3, encoding a multifunctional galactose-binding lectin . Based on our work and published study, we guess EED might be a double-sword in LAML that loss-of-functions of EED contributes to LAML tumorigenesis and increased expression of EED predicts poor prognosis in LAML.
In order to investigate the regulatory network associated with EED expression, the EED co-expressed genes were identified and the KEGG pathway was enriched. In our work, we found, the co-expressed genes were significantly enriched in Fanconi anemia pathway, cell cycle, Oocyte meiosis, DNA replication, which also had the high connectivity with those co-expressed genes.
Fanconi anemia (FA) is a rare autosomal recessive cancer-prone inherited bone marrow failure syndrome, the major complications of which are aplastic anemia, acute myeloid leukemia (LAML) and myelodysplastic syndrome (MDS) (Alter 2014) . BRCA1 and BRCA2 are DNA repair associated proteins. FA patients carry FANCD1/BRCA2 mutations are susceptible to cancer risk, including leukemia, brain tumor or combinations (Alter 2014; Biswas et al. 2011 ). In our work, Fanconi anemia proteins, including FANCB, FANCD2, FANCI, FANCL and FANCM, co-expressed with EED and enriched in Fanconi anemia pathway. It is reported that hyper-methylation of FANCL promoter regions are found in sporadic acute leukemia (Hess et al. 2008 ). In addition, genetic variant of human homologous recombination-associated gene RMI, which co-expressed with EED and enriched in Fanconi anemia pathway, significantly increase the risk of LAML (Broberg et al. 2007 ).
Cell cycle is commonly dysregulated in various types of tumor. In our work, cell cycle proteins, CCNB1, CCNB2, CCNE2, CDC27, CDC6, CDC7, CDK1, co-expressed with EED and significantly enriched in cell cycle pathway. LAML patients with higher level of nuclear CDK1 in their leukemic blasts had the poorer clinical outcome and CDK1 modulate the level of p27 (kip) and AKT phosphorylation in response to ATRA treatment (Hedblom et al. 2013) . The recent Phase I study of the novel CDK1 inhibitor terameprocol in patients with leukemia shows that 5 out 16 patients with advanced LAML or MDS have stable disease greater/equal to 2 months though reducing the expression of CDK1 and phosphor-AKT (Tibes et al. 2015) .
AURKA and PPP2R5E, co-expressed with EED, were significantly enriched in oocyte meiosis pathway. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high blood cell counts in LAML patients (Lucena-Araujo et al. 2011).
Over-expression of AEG-1 is essential for carcinogenesis role in human LAML through up-regulation of Akt mediated by AURKA activation (Long et al. 2013) . PPP2R5E is commonly down-regulated and influence on the oncogenic potential of leukemia cells (Cristobal et al. 2013 ).
In our study, we found EED expression was significantly increased in DLBC compared with normal subjects and it was also significantly increased in DLBC compared with LAML subjects. PRC2 and H3K27me3 might paly opposite roles in LAML and DLBC. Decreased EZH2 predicts poor prognosis in LAML and high abundance of H3K27me3 predicts poor prognosis in DLBC (Oh et al. 2014; Shi et al. 2013) . Increased EED expression might paly essential roles in DLBC tumorigenesis.
EED mRNA expression was negatively correlated with DNA methylation in DLBC, which indicated that high expression of EED might be due to hypo-methylation in DLBC. In actually, there are cross-talk between DNA methylation and histone methylation in genes (Cedar & Bergman 2009 ).
Different epigenetic factors synergistically regulate activation and silencing of gene expression in various biological processes. Our study displayed that EED expression was not associated clinical stage and prognosis of DLBC, which was consistent with published article that PRC2 expression is not correlated with OS and RFS of DLBC and high abundance of H3K27me3 predicts shorter OS and RFS in DLBC patients (Oh et al. 2016; Oh et al. 2014) .
ARPC5, RELT and DPP3 (data not shown) had the most strongly positive correlation with EED expression and NR1D2, PAIP2B and GPD1L ( data not shown) had the most strongly negative correlation with EED expression in DLBC. It is reported that DPP3 is overexpressed in breast cancer and increased mRNA expression of predict unfavorable prognosis in breast cancer patients (especially in ER + breast cancer) (Lu et al. 2017) . NR1D2 regulates glioblastoma cell proliferation and motility (Yu et al. 2018 ). The significance of abovementioned genes in DLBC tumorigenesis and prognosis need to be further investigated in our future work.
The genes co-expressed with EED in DLBC were significantly enriched three pathways, including
Pathogenic Escherichia coli infection, Shigellosis and Legionellosis, involved in pathogen infection and immunity response, which echoes the pathogenesis of DLBC. In fact, infectious agents have been implicated as the cause of non-hodgkin lymphoma (NHL). There are three types of pathogens that cause NHL, the first type is viruses that can directly transform lymphocytes, such as EBV, HPV8, and HTLV-1, the second type is HIV virus, which that cause loss of CD4+T cells and indirectly induce NHL, the third type is viruses that induce NHL through chronic immune stimulation, such as HCV (Engels 2007) . DLBC with EB infection is associated with the rapidly deteriorating clinical course with treatment response, survival and progression-free survival (Park et al. 2007 ).
In addition, ZNF252P and XRCC5 were the shared genes among EED co-expressed genes in LAML and DLBC. ZNF252P was positively correlated with EED expression in LAML; however, it was negatively correlated with EED expression in DLBC. XRCC5 encodes X-ray repair cross complementing 5 and functions as modulating chromosomal stability. It is down-regulated both in non-small cell lung cancer and breast cancer with hyper-methylation in promotor region; the SNPs in XRCC5 promoter region might be susceptible to breast cancer Rajaei et al. 2014) .
EED gene possesses potential application value in the prevention and treatment of DLBC. In fact, A breakthrough has been made in DLBC targeted therapy by using an EED protein inhibitor.
Compound 43, a small molecular compound, allosterically inactivates the methyltransferase activity of PRC2 complex through inhibiting with its adaptor protein of EED, which contribute to decrease tumor size in xenograft model of lymphoma (Yang & Wang 2017) . In the preclinical study, compound 43 have the roubst anticancer efficacy based on oral administration (Huang et al. 2017 ).
Therefore, targeted inhibition of the function of EED protein is an effective anticancer strategy. 
